InvestorsHub Logo
Followers 0
Posts 4
Boards Moderated 0
Alias Born 08/03/2014

Re: None

Wednesday, 08/20/2014 8:19:16 PM

Wednesday, August 20, 2014 8:19:16 PM

Post# of 232336
Practical problem: If patients can't be reliably and economically tested as R5-exclusive, then doctors/providers will be discouraged from pursuing this line of treatment. This is just another competitive advantage among many favoring the incumbent Maraviroc.

Nader was wrong about trofile testing with Maraviroc. Pfizer did indeed run into the similar problems, even with higher loads.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News